JP2024063143A5 - - Google Patents

Info

Publication number
JP2024063143A5
JP2024063143A5 JP2024030700A JP2024030700A JP2024063143A5 JP 2024063143 A5 JP2024063143 A5 JP 2024063143A5 JP 2024030700 A JP2024030700 A JP 2024030700A JP 2024030700 A JP2024030700 A JP 2024030700A JP 2024063143 A5 JP2024063143 A5 JP 2024063143A5
Authority
JP
Japan
Prior art keywords
subject
pharmaceutically acceptable
acceptable salt
composition
need
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024030700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024063143A (ja
JP7841008B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2019/034505 external-priority patent/WO2019232120A1/en
Application filed filed Critical
Publication of JP2024063143A publication Critical patent/JP2024063143A/ja
Publication of JP2024063143A5 publication Critical patent/JP2024063143A5/ja
Application granted granted Critical
Publication of JP7841008B2 publication Critical patent/JP7841008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024030700A 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩 Active JP7841008B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862678025P 2018-05-30 2018-05-30
US62/678,025 2018-05-30
US201862726612P 2018-09-04 2018-09-04
US62/726,612 2018-09-04
US201962822336P 2019-03-22 2019-03-22
US62/822,336 2019-03-22
GC201937661 2019-05-28
GC2019/37661 2019-05-28
PCT/US2019/034505 WO2019232120A1 (en) 2018-05-30 2019-05-30 Pharmaceutically acceptable salts of sepiapterin
JP2020566701A JP7778477B2 (ja) 2018-05-30 2019-05-30 セピアプテリンの薬学的に許容される塩

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020566701A Division JP7778477B2 (ja) 2018-05-30 2019-05-30 セピアプテリンの薬学的に許容される塩

Publications (3)

Publication Number Publication Date
JP2024063143A JP2024063143A (ja) 2024-05-10
JP2024063143A5 true JP2024063143A5 (cg-RX-API-DMAC7.html) 2026-02-20
JP7841008B2 JP7841008B2 (ja) 2026-04-06

Family

ID=68699017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020566701A Active JP7778477B2 (ja) 2018-05-30 2019-05-30 セピアプテリンの薬学的に許容される塩
JP2024030700A Active JP7841008B2 (ja) 2018-05-30 2024-02-29 セピアプテリンの薬学的に許容される塩

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020566701A Active JP7778477B2 (ja) 2018-05-30 2019-05-30 セピアプテリンの薬学的に許容される塩

Country Status (13)

Country Link
US (1) US12637465B2 (cg-RX-API-DMAC7.html)
EP (1) EP3807279B1 (cg-RX-API-DMAC7.html)
JP (2) JP7778477B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210038848A (cg-RX-API-DMAC7.html)
CN (1) CN112543758A (cg-RX-API-DMAC7.html)
AU (2) AU2019277372B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020024332A2 (cg-RX-API-DMAC7.html)
CA (1) CA3102070A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003101A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020016582A2 (cg-RX-API-DMAC7.html)
IL (1) IL279101A (cg-RX-API-DMAC7.html)
MX (1) MX2020012978A (cg-RX-API-DMAC7.html)
WO (1) WO2019232120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) * 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) * 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
CA3165636A1 (en) 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
CN114621198B (zh) * 2020-12-11 2025-01-21 北京夏禾科技有限公司 有机电致发光材料及其器件
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US5753656A (en) * 1994-08-05 1998-05-19 Suntory Limited Method for treating spinocerebellar degeneration
WO1997007236A1 (en) 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
JP2007509909A (ja) 2003-10-31 2007-04-19 アルタナ ファルマ アクチエンゲゼルシャフト 呼吸器疾患の治療のためのbh4の使用
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
KR20160065998A (ko) 2007-04-11 2016-06-09 바이오마린 파머수티컬 인크. 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
LT2262790T (lt) 2008-03-10 2017-08-25 Takeda Pharmaceutical Company Limited Benzimidazolo junginio kristalas
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
IN2012DN01453A (cg-RX-API-DMAC7.html) 2009-08-20 2015-06-05 Novartis Ag
JP5066756B2 (ja) * 2010-04-22 2012-11-07 学校法人日本大学 脳機能障害予防・改善用の薬剤及び飲食物
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
WO2017218421A1 (en) * 2016-06-13 2017-12-21 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
WO2018019931A1 (en) 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) * 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Similar Documents

Publication Publication Date Title
JP2021525729A5 (cg-RX-API-DMAC7.html)
JP2021527031A5 (cg-RX-API-DMAC7.html)
JP2024069192A5 (cg-RX-API-DMAC7.html)
JP2023549226A5 (cg-RX-API-DMAC7.html)
JP2008540486A (ja) Pde4インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物
FI3801536T3 (fi) Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
JP2021505575A5 (cg-RX-API-DMAC7.html)
FI3801534T3 (fi) Fenyyliketonurian hoito sepiapteriinilla
JP2021525746A5 (cg-RX-API-DMAC7.html)
US20220096475A1 (en) Method for treating sarcoidosis-associated pulmonary hypertension
JP2024019691A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
EP3609481A2 (en) Methods of treating developmental encephalopathies
JP2022514537A5 (cg-RX-API-DMAC7.html)
JPH1036260A (ja) 抗ガン剤の効力増強方法
KR20010032009A (ko) 수면성 무호흡의 치료에 미타자핀을 사용하는 방법
CZ111897A3 (cs) Použití indolových derivátů pro výrobu léčiv a farmaceutický prostředek
JP2014513130A5 (cg-RX-API-DMAC7.html)
JPS61286326A (ja) パ−キンソン病治療薬
US20030050329A1 (en) Synergistic combination comprising roflumilast and a PDE-3 inhibitor
JP2012502105A5 (cg-RX-API-DMAC7.html)
JP2004501153A5 (cg-RX-API-DMAC7.html)
TWI439269B (zh) 4-環丙基甲氧基-n-(3,5-二氯-1-氧離子基吡啶-4-基)-5-(甲氧基)吡啶-2-甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途
US20070049599A1 (en) Use of bh4 for the treatment of respiratory diseases
JP3865450B2 (ja) パーキンソニズム治療剤
JP2761104B2 (ja) 脊髄小脳変性症治療剤